• <dfn id="q240u"></dfn>
    • Avagacestat (BMS-708163)

      中文名稱:塞來西布

      Avagacestat (BMS-708163)是口服生物有效的,選擇性的γ-分泌酶抑制劑,作用于Aβ40Aβ42時,IC50分別為0.3 nM和0.27 nM,比作用于Notch選擇性高193倍。Phase 2。

      Avagacestat (BMS-708163) Chemical Structure

      Avagacestat (BMS-708163) Chemical Structure

      CAS: 1146699-66-2

      規(guī)格 價格 庫存 購買數(shù)量
      5mg 1403.72 現(xiàn)貨
      10mg 2620.13 現(xiàn)貨
      50mg 7967.17 現(xiàn)貨
      200mg 15700 現(xiàn)貨
      1g 39900 現(xiàn)貨
      更大包裝 有超大折扣

      400-668-6834

      [email protected]

      免費分裝
      免費預溶

      Avagacestat (BMS-708163)相關(guān)產(chǎn)品

      細胞實驗數(shù)據(jù)示例

      細胞系 實驗類型 給藥濃度 孵育時間 活性描述 文獻信息(PMID)
      human IMR32 cell Function assay 2 h Inhibition of gamma-secretase in human IMR32 cell membrane using APP as substrate after 2 hrs by ELISA, IC50=0.13 nM
      human IMR32 cell Function assay 2 h Inhibition of gamma-secretase in human IMR32 cell membrane using Notch as substrate after 2 hrs by ELISA, IC50=1.5 nM
      human H4 cells Function assay Inhibition of gamma secretase-mediated amyloid beta42 production in human H4 cells expressing human APP swedish mutant, IC50=0.225 μM
      HEK293 cells Function assay Inhibition of gamma-secretase in HEK293 cells after overnight incubation by Western blotting analysis, IC50=1.2 nM
      CHO cells Function assay Inhibition of gamma-secretase in CHO cells assessed expressing APPSw assessed as inhibition of amyloid beta(1 to x) secretion after overnight incubation by ELISA, ED50=1.2 nM
      human 786-0 cell Growth inhibition assay Inhibition of human 786-0 cell growth in a cell viability assay, IC50=0.32173 μM
      human NCI-H810 cell Growth inhibition assay Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50=0.42598 μM
      human IGR-1 cell Growth inhibition assay Inhibition of human IGR-1 cell growth in a cell viability assay, IC50=1.04778 μM
      human SK-MEL-3 cell Growth inhibition assay Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=1.49922 μM
      human HT-1080 cell Growth inhibition assay Inhibition of human HT-1080 cell growth in a cell viability assay, IC50=2.48764 μM
      human NCI-H23 cell Growth inhibition assay Inhibition of human NCI-H23 cell growth in a cell viability assay, IC50=3.9322 μM
      human Calu-6 cell Growth inhibition assay Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=4.96014 μM
      human CAPAN-1 cell Growth inhibition assay Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50=5.17886 μM
      human COLO-668 cell Growth inhibition assay Inhibition of human COLO-668 cell growth in a cell viability assay, IC50=5.40221 μM
      human TE-6 cell Growth inhibition assay Inhibition of human TE-6 cell growth in a cell viability assay, IC50=6.19082 μM
      human LCLC-97TM1 cell Growth inhibition assay Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50=10.0886 μM
      human CAS-1 cell Growth inhibition assay Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=13.671 μM
      human RPMI-2650 cell Growth inhibition assay Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50=13.8124 μM
      human MDA-MB-157 cell Growth inhibition assay Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50=14.2431 μM
      human KINGS-1 cell Growth inhibition assay Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50=14.3762 μM
      human BB49-HNC cell Growth inhibition assay Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=14.4138 μM
      human SK-UT-1 cell Growth inhibition assay Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50=14.6882 μM
      human EW-11 cell Growth inhibition assay Inhibition of human EW-11 cell growth in a cell viability assay, IC50=14.8832 μM
      human D-502MG cell Growth inhibition assay Inhibition of human D-502MG cell growth in a cell viability assay, IC50=14.9034 μM
      human MMAC-SF cell Growth inhibition assay Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50=15.0833 μM
      human NCI-H1648 cell Growth inhibition assay Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50=15.778 μM
      human NCI-H292 cell Growth inhibition assay Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50=15.8806 μM
      human NMC-G1 cell Growth inhibition assay Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=16.6293 μM
      human SAS cell Growth inhibition assay Inhibition of human SAS cell growth in a cell viability assay, IC50=17.7812 μM
      human HCT-116 cell Growth inhibition assay Inhibition of human HCT-116 cell growth in a cell viability assay, IC50=18.7965 μM
      human SBC-5 cell Growth inhibition assay Inhibition of human SBC-5 cell growth in a cell viability assay, IC50=19.03 μM
      點擊查看更多細胞系數(shù)據(jù)

      生物活性

      產(chǎn)品描述 Avagacestat (BMS-708163)是口服生物有效的,選擇性的γ-分泌酶抑制劑,作用于Aβ40Aβ42時,IC50分別為0.3 nM和0.27 nM,比作用于Notch選擇性高193倍。Phase 2。
      特性 BMS-708163作用于Notch過程似乎比semagacestat (LY450139)效果要好,且所需量要少
      靶點
      Aβ42 [1]
      (in H4-8Sw cells)
      Aβ40 [1]
      (in H4-8Sw cells)
      0.27 nM 0.3 nM
      體外研究(In Vitro)
      體外研究活性 BMS-708163 抑制Notch 過程時顯示出低選擇性。 [1]
      體內(nèi)研究(In Vivo)
      體內(nèi)研究活性 鼠和犬口服處理BMS-708163 明顯且長期降低腦,血漿,腦脊液中的Aβ40 水平。BMS-708163作用于犬時,沒有劑量限制影響(用3 mg/kg BMS-708163處理6個月內(nèi)的犬)。[1]
      動物實驗 Animal Models 雌性Harlan Sprague Dawley鼠或 ATM-405-142K9,7到10月大的 na?ve II級犬。
      Dosages 10 mg/kg (鼠) 或2.5 mg/kg (犬)
      Administration 每天口服飼喂
      NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
      NCT01002079 Completed
      Alzheimer Disease
      Bristol-Myers Squibb|PRA Health Sciences
      August 2010 Phase 1
      NCT01057030 Completed
      Alzheimer Disease
      Bristol-Myers Squibb
      March 2010 Phase 1
      NCT01042314 Completed
      Alzheimer Disease
      Bristol-Myers Squibb
      January 2010 Phase 1
      NCT01039194 Completed
      Alzheimer Disease
      Bristol-Myers Squibb
      January 2010 Phase 1
      NCT00979316 Completed
      Alzheimer Disease
      Bristol-Myers Squibb
      September 2009 Phase 1
      NCT00890890 Terminated
      Alzheimer''s Disease
      Bristol-Myers Squibb
      May 2009 Phase 2
      • http://pubs.acs.org/doi/abs/10.1021/ml1000239

      化學信息&溶解度

      分子量 520.88 分子式

      C20H17ClF4N4O4S

      CAS號 1146699-66-2 SDF Download Avagacestat (BMS-708163) SDF
      Smiles C1=CC(=CC=C1S(=O)(=O)N(CC2=C(C=C(C=C2)C3=NOC=N3)F)C(CCC(F)(F)F)C(=O)N)Cl
      儲存條件(自收到貨起)

      體外溶解度
      批次:

      DMSO : 104 mg/mL ( (199.66 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO)

      Water : Insoluble

      Ethanol : Insoluble

      摩爾濃度計算器

      體內(nèi)溶解配方
      批次:

      現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑

      動物體內(nèi)配方計算器

      實驗計算

      摩爾濃度計算器

      質(zhì)量 濃度 體積 分子量

      動物體內(nèi)配方計算器(澄清溶液)

      第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)

      mg/kg g μL

      第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)

      % DMSO % % Tween 80 % ddH2O
      %DMSO %

      計算結(jié)果:

      工作液濃度: mg/ml;

      DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);

      體內(nèi)配方配制方法:μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。

      體內(nèi)配方配制方法:μL DMSO母液,加入μL Corn oil,混勻澄清。

      注意:1. 首先保證母液是澄清的;
      2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。

      技術(shù)支持

      在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱[email protected],直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。

      操作手冊

      如果有其他問題,請給我們留言。

      * 必填項

      請輸入您的姓名
      請輸入您的郵箱地址 請輸入一個有效的郵箱地址
      請寫點東西給我們
      在線咨詢
      聯(lián)系我們
        • <dfn id="q240u"></dfn>
        • 四虎8888免费视频网站 | 啊灬啊灬啊灬快灬高潮了女 | 五月天福利视频 | 女的张开腿让男的捅 | 中文字幕一区二区三区AⅤ吉川 |